References
1. Vodenkova, S., et al., 5-fluorouracil and other fluoropyrimidines in
colorectal cancer: Past, present and future. Pharmacol Ther, 2020.206 : p. 107447.
2.
Wolpin,
B.M. and R.J. Mayer, Systemic treatment of colorectal cancer.
Gastroenterology, 2008. 134 (5): p. 1296-310.
3. van der Velden, D.L., F.L. Opdam and E.E. Voest, TAS-102 for
Treatment of Advanced Colorectal Cancers That Are No Longer Responding
to Other Therapies. Clin Cancer Res, 2016. 22 (12): p. 2835-9.
4.
Casado,
E., et al., UFT (tegafur-uracil) in rectal cancer. Ann Oncol, 2008.19 (8): p. 1371-1378.
5.
Dahan,
L., et al., Modulation of cellular redox state underlies antagonism
between oxaliplatin and cetuximab in human colorectal cancer cell lines.
Br J Pharmacol, 2009. 158 (2): p. 610-20.
6.
Zou,
W., J.D. Wolchok and L. Chen, PD-L1 (B7-H1) and PD-1 pathway blockade
for cancer therapy: Mechanisms, response biomarkers, and combinations.
Sci Transl Med, 2016. 8 (328): p. 328rv4.
7. Fiorentini, C., et al., Gut Microbiota and Colon Cancer: A Role for
Bacterial Protein Toxins? Int J Mol Sci, 2020. 21 (17).
8.
Huus,
K.E., et al., Commensal Bacteria Modulate Immunoglobulin A Binding in
Response to Host Nutrition. Cell Host Microbe, 2020. 27 (6): p.
909-921.e5.
9. Hayden, H.S., et al., Fecal dysbiosis in infants with cystic fibrosis
is associated with early linear growth failure. Nat Med, 2020.26 (2): p. 215-221.
10. Dubinsky, V., et al., Predominantly Antibiotic-resistant Intestinal
Microbiome Persists in Patients with Pouchitis Who Respond to Antibiotic
Therapy. Gastroenterology, 2020. 158 (3): p. 610-624.e13.
11.
Brennan,
C.A. and W.S. Garrett, Fusobacterium nucleatum - symbiont, opportunist
and oncobacterium. Nat Rev Microbiol, 2019. 17 (3): p. 156-166.
12. Komiya, Y., et al., Patients with colorectal cancer have identical
strains of Fusobacterium nucleatum in their colorectal cancer and oral
cavity. Gut, 2019. 68 (7): p. 1335-1337.
13.
Kwong,
T., et al., Association Between Bacteremia From Specific Microbes and
Subsequent Diagnosis of Colorectal Cancer. Gastroenterology, 2018.155 (2): p. 383-390.e8.
14. Yu, T., et al., Fusobacterium nucleatum Promotes Chemoresistance to
Colorectal Cancer by Modulating Autophagy. Cell, 2017. 170 (3):
p. 548-563.e16.
15.
Zhang,
S., et al., Fusobacterium nucleatum promotes chemoresistance to
5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
J Exp Clin Cancer Res, 2019. 38 (1): p. 14.
16. Sears, C.L., A.L. Geis and F. Housseau, Bacteroides fragilis
subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin
Invest, 2014. 124 (10): p. 4166-72.
17.
Chung,
L., et al., Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic
Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell
Host Microbe, 2018. 23 (2): p. 203-214.e5.
18. Multidrug-resistant bacteroides fragilis–Seattle, Washington,
2013. MMWR Morb Mortal Wkly Rep, 2013. 62 (34): p. 694-6.
19.
Lieuw-a-Fa,
M., et al., Sepsis from liver abscesses in metastatic colorectal
carcinoma after chemoimmunotherapy. J Clin Oncol, 2008. 26 (8):
p. 1381-2.
20. Butt, J., et al., Association of Pre-diagnostic Antibody Responses
to Escherichia coli and Bacteroides fragilis Toxin Proteins with
Colorectal Cancer in a European Cohort. Gut Microbes, 2021.13 (1): p. 1-14.
21.
Liu,
Q.Q., et al., Enterotoxigenic Bacteroides fragilis induces the stemness
in colorectal cancer via upregulating histone demethylase JMJD2B. Gut
Microbes, 2020. 12 (1): p. 1788900.
22. Ge, W., et al., High-risk Stage III colon cancer patients identified
by a novel five-gene mutational signature are characterized by
upregulation of IL-23A and gut bacterial translocation of the tumor
microenvironment. Int J Cancer, 2020. 146 (7): p. 2027-2035.
23.
O’Leary,
K., MYC inhibition, courtesy of E. coli. Nat Rev Cancer, 2021.21 (4): p. 214-215.
24. Holmes, C.L., et al., Pathogenesis of Gram-Negative Bacteremia. Clin
Microbiol Rev, 2021. 34 (2).
25.
Lucas,
C., et al., Autophagy of Intestinal Epithelial Cells Inhibits Colorectal
Carcinogenesis Induced by Colibactin-Producing Escherichia coli in
Apc(Min/+) Mice. Gastroenterology, 2020. 158 (5): p. 1373-1388.
26. Serna, G., et al., Fusobacterium nucleatum persistence and risk of
recurrence after preoperative treatment in locally advanced rectal
cancer. Ann Oncol, 2020. 31 (10): p. 1366-1375.
27. Chen, Y., et al., Prognostic impact of the Fusobacterium nucleatum
status in colorectal cancers. Medicine (Baltimore), 2019.98 (39): p. e17221.
28. Jing, L., et al., Composition of fecal microbiota in low-set rectal
cancer patients treated with FOLFOX. Ther Adv Chronic Dis, 2020.11 : 2040622320904293.
29.
Deng,
X., et al., Comparison of Microbiota in Patients Treated by Surgery or
Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for
Colorectal Cancer Therapy. Front Microbiol, 2018. 9 : 1607.
30. Li, J., et al., Microbiome characteristics and Bifidobacterium
longum in colorectal cancer patients pre- and post-chemotherapy.
Translational Cancer Research, 2020. 9 (4): 2178-2190.
31. John, N., et al., Pilot trial of genetically modified, attenuated
Salmonella expressing the E. coli cytosine deaminase gene in refractory
cancer patients. Cancer Gene Therapy, 2003. 10 : 737-744.
32. Clemens, U., et al., Double-blind Randomised Placebo-controlled
Phase III Study of an E. coli Extract plus 5-Fluorouracil versus
5-Fluorouracil in Patients with Advanced Colorectal Cancer, 2001.51 (4): 332-8.
33. Maria, L., et al., Influence of varying doses of
granulocyte-macrophage colony-stimulating factor on pharmacokinetics and
antibody-dependent cellular cytotoxicity. Cancer Immunol Immunotherapy,
2008. 57 : 379–388.
34.
Shapiro,
J., et al., A pilot study of interferon alpha-2a, fluorouracil, and
leucovorin given with granulocyte-macrophage colony stimulating factor
in advanced gastrointestinal adenocarcinoma. Clin Cancer Res 1999.5 (9).
35. Mann, R., Hewitt, C.E. & Gilbody, S.M. Assessing the quality of
diagnostic studies using psychometric instruments: applying QUADAS. Soc
Psychiat Epidemiol, 2009. 44 (300).